The Technical Analyst
Sarepta Therapeutics Inc [SRPT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sarepta Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.78% $129.66
America/New_York / 26 apr 2024 @ 14:40
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 12 169 mill |
| EPS: | -5.80 |
| P/E: | -22.36 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 93.86 mill |
| Avg Daily Volume: | 0.838 mill |
| RATING 2024-04-26 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -22.36 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.80x |
| Company: PE -22.36 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 126.10 - 133.22 ( +/- 2.74%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-08 | Wigzell Hans Lennart Rudolf | Buy | 15 000 | Common Stock |
| 2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 3 155 | Common Stock |
| 2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 11 745 | Common Stock |
| 2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 100 | Common Stock |
| 2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 15 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 36.03 |
| Last 100 transactions |
| Buy: 408 419 | Sell: 153 150 |
Forecast:
16:00 - $129.62
Live Trading Signals (every 1 min)
Forecast
1: 14:49 - $129.65
Forecast 2: 15:39 - $129.54
Forecast 3: 16:00 - $129.62
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $129.66 (1.78% ) |
| Volume | 0.423 mill |
| Avg. Vol. | 0.838 mill |
| % of Avg. Vol | 50.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SRPT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $127.34 | N/A | Active |
|---|
SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-24 08:30:00 - Press Release
Sarepta Therapeutics To Announce First Quarter 2024 Financial Results
Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the nasdaq global market closes on wednesday, may 1, 2024. subsequently, at 4:30 p.m. e.t., the company will host a conference call to discuss its first quarter 2024 financial results. the event will be webcast live under the investor relations section of sarepta's website at https://investorrelations.sare.
2024-03-29 16:00:00 - Press Release
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, granted equity awards on march 29, 2024 that were previously approved by the compensation committee of its board of directors under sarepta's 2024 employment commencement incentive plan, as a material inducement to employment to 8 individuals hired by sarepta in march 2024. the equity awards were approved in accordance with nasdaq listing rule 5635(c)(4). the.
2024-03-04 08:30:00 - Press Release
Sarepta Therapeutics To Present At Upcoming Investor Conferences
Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences: leerink partners global biopharma conference on mon., march 11, 2024, at 10:00 a.m. e.t at the fontainebleau hotel in miami, fla. barclays 26th annual global healthcare conference on tue., march 12, 2024, at 3:05 p.m. e.t. at the loews miami beach ho.
2024-02-29 18:16:00 - Press Release
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, granted equity awards on feb. 29, 2024 that were previously approved by the compensation committee of its board of directors under sarepta's 2014 employment commencement incentive plan, as a material inducement to employment to 5 individuals hired by sarepta in february 2024. the equity awards were approved in accordance with nasdaq listing rule 5635(c)(4). th.
2024-02-29 09:00:00 - Press Release
Sarepta Therapeutics Announces Call For Applications For The 7th Annual Route 79, The Duchenne Scholarship Program
Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced the official opening of route 79, the duchenne scholarship program for the 2024-2025 academic year. academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with duchenne muscular dystrophy and five siblings of individuals living with duchenne. applications will be accepted until monday, may 13, 2024, at 11:59 p.
Latest News
2024-04-24 08:30:00 - Business Wire
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sare.
2024-04-23 14:21:06 - Zacks Investment Research
GSK Gears Up for Q1 Earnings: Here's What to Expect
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
2024-04-06 08:45:00 - The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in April
Amgen's lineup and pipeline should help its financial results and keep its dividend intact. While lesser known, Sarepta is proving itself to be a highly innovative biotech company.
2024-03-29 12:36:59 - Zacks Investment Research
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
2024-03-13 08:00:00 - The Motley Fool
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Regenxbio reported some favorable data from a phase 1 clinical trial. Sarepta Therapeutics has a medicine on the market for the same target.
2024-03-08 05:45:00 - The Motley Fool
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
Biopharma company Sarepta Therapeutics is on the verge of reaching sustained profits. Last year was miserable for Enphase Energy, and this year isn't likely to be much better thanks to the tepid demand for residential solar solutions.
2024-03-04 09:47:00 - The Motley Fool
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Sarepta Therapeutics is trying to widen its market for Elevidys. Regulators should deliver a verdict in early March.
2024-02-29 13:36:03 - Zacks Investment Research
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
2024-02-28 19:33:09 - Seeking Alpha
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
2024-02-28 19:01:18 - Zacks Investment Research
Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.